Introduction {#section1-2333794X19845074}
============

Adrenal insufficiency is decreased or deficient production of glucocorticoids and/or mineralocorticoids that has potential to be life-threatening.^[@bibr1-2333794X19845074],[@bibr2-2333794X19845074]^ First described by Thomas Addison in 1855, this disease can present insidiously with weakness, fatigue, weight loss, abdominal pain, nausea, vomiting, hypotension, salt cravings, depression, anxiety, as well as mucosal and epithelial hyperpigmentation.^[@bibr1-2333794X19845074],[@bibr2-2333794X19845074]^

Adrenal insufficiency is related to dysfunction of the hypothalamic-pituitary-adrenal axis.^[@bibr1-2333794X19845074],[@bibr2-2333794X19845074]^ Primary disease refers to pathology of the adrenal cortex; secondary refers to inadequate or deficient release of adrenocorticotropic hormone (ACTH) or inappropriate response to this hormone by the adrenal gland; and tertiary refers to disordered hypothalamic production of corticotropin releasing hormone.^[@bibr1-2333794X19845074]^

Primary adrenal disease occurs more commonly in women, frequently presenting between 30 and 50 years of life. Tuberculosis was formerly the most common cause; however, autoimmune adrenal insufficiency is now responsible for close to 90% of cases of primary adrenal insufficiency.^[@bibr1-2333794X19845074][@bibr2-2333794X19845074]-[@bibr3-2333794X19845074]^ Infectious diseases, neoplasia, adrenalectomy, and genetic causes account for other etiologies.^[@bibr2-2333794X19845074]^ Among pediatric patients, most cases are related to genetic causes, while only a small fraction are related to autoimmune disease.^[@bibr1-2333794X19845074],[@bibr2-2333794X19845074]^ Secondary insufficiency is more common than primary in all age groups and often develops around 60 years of age.^[@bibr1-2333794X19845074]^ Tertiary insufficiency is most often caused by suppression of the hypothalamic-pituitary-adrenal axis by long-term steroid use.^[@bibr1-2333794X19845074]^

Approximately 80% to 90% of cases of primary adrenal insufficiency have autoimmune etiology, with approximately 60% of those being related to an APS.^[@bibr1-2333794X19845074],[@bibr4-2333794X19845074]^ APSs refer to various clusters or combinations of autoimmune disorders that are rare and consist of 2 or more concomitant autoimmune-mediated diseases.^[@bibr5-2333794X19845074]^ To make a diagnosis of an APS, an autoimmune basis for each component of the syndrome must be confirmed.^[@bibr3-2333794X19845074]^

APS type 1, or autoimmune polyglandular, candidiasis, ectodermal dystrophy (APECED), is an autosomal recessive disorder related to mutations in the autoimmune regulator (AIRE) gene. Often seen in groups of people indigenous to Finland and Sardinia, APS type 1 is notable by adrenocortical insufficiency, hypoparathyroidism, candidiasis, dental enamel hypoplasia, and nail dystrophy.^[@bibr1-2333794X19845074],[@bibr6-2333794X19845074]^ Diabetes, pernicious anemia, hypothyroidism, and hypogonadism are examples of other autoimmune disorders that may be associated with APS type 1.^[@bibr1-2333794X19845074],[@bibr7-2333794X19845074]^ APS type 1 generally manifests in infancy, between ages 3 and 5 years, or in early adolescence; as such, APS type 1 is also known as juvenile autoimmune poly-endocrinopathy.^[@bibr5-2333794X19845074]^ APS type 1 is considered very rare, with an incidence of less than 1:100 000/year.^[@bibr5-2333794X19845074]^

APS type 2, also known as Schmidt's or Carpenter's syndrome, is a cluster of autoimmune diseases characterized by autoimmune adrenal insufficiency and thyroid disease with or without type 1 diabetes.^[@bibr1-2333794X19845074],[@bibr5-2333794X19845074][@bibr6-2333794X19845074]-[@bibr7-2333794X19845074]^ Autoimmune diseases that may be associated include hypogonadism, hypopituitarism, immunoglobulin A deficiency, myasthenia gravis, celiac disease, and vitiligo.^[@bibr1-2333794X19845074],[@bibr5-2333794X19845074][@bibr6-2333794X19845074]-[@bibr7-2333794X19845074]^ APS type 2 is more prevalent than APS type 1, often associated with multiple autoimmune conditions, and is more common in women than men.^[@bibr1-2333794X19845074],[@bibr3-2333794X19845074]^ There is a peak incidence between 20 and 60 years of life, with the third or fourth decades being the most common.^[@bibr3-2333794X19845074],[@bibr5-2333794X19845074],[@bibr6-2333794X19845074]^ In contrast to APS type 1, which has an association with a defect in the AIRE gene, APS type 2 is associated with genetic abnormalities of class II HLA alleles.^[@bibr3-2333794X19845074],[@bibr6-2333794X19845074],[@bibr7-2333794X19845074]^ APS type 2 has a male-to-female ratio of 1:3 and is relatively common with an incidence of 1-2:10 000/year.^[@bibr5-2333794X19845074]^ Given predilection to concomitant diseases, regular surveillance is crucial to screen for other conditions.^[@bibr7-2333794X19845074]^

Clinical signs of adrenal insufficiency include hypoglycemia, hyperpigmentation, hyponatremia, hyperkalemia, and hypotension.^[@bibr1-2333794X19845074]^ Symptoms are nonspecific, including fatigue, weakness, nausea, vomiting, abdominal pain, anorexia, myalgias, and salt craving.^[@bibr1-2333794X19845074]^ As such, diagnosis begins with a high index of suspicion. Laboratory studies consistent with primary insufficiency includes elevated early morning ACTH, elevated plasma renin activity, low aldosterone, hyponatremia, and hyperkalemia.^[@bibr1-2333794X19845074]^ Whereas ACTH is elevated in primary insufficiency, ACTH is low or normal in secondary and tertiary insufficiency.^[@bibr1-2333794X19845074]^ An early morning cortisol level with a level \<3 µg/dL is suggestive of adrenal insufficiency.^[@bibr3-2333794X19845074]^ The "gold standard" cosyntropin (synthetic ACTH) stimulation test is often used for diagnosis, wherein synthetic ACTH is administered intravenously, with cortisol level checked 30 and 60 minutes after administration.^[@bibr1-2333794X19845074][@bibr2-2333794X19845074]-[@bibr3-2333794X19845074]^ Cortisol levels \<14 µg/dL are positive.^[@bibr1-2333794X19845074],[@bibr3-2333794X19845074]^ Diagnosis of specific APS syndromes is achieved by screening for each individual disease process suspected.^[@bibr5-2333794X19845074]^

Ethical Approval and Informed Consent {#section2-2333794X19845074}
-------------------------------------

This is a case report requiring only chart review and literature review, without any direct intervention or harm to the patient referred to in this case, and as such, informed consent and ethical approval was not needed.

Case Report {#section3-2333794X19845074}
===========

A 15-year-old male presented to a local hospital with fatigue, fever, abdominal pain, nausea, and vomiting for a few days prior to presentation. He reported a severe viral illness roughly 6 weeks prior to his presentation. Laboratory studies in the emergency department were significant for hyponatremia and an elevated thyroid-stimulating hormone (TSH). The remaining results, including complete blood count, hepatic panel, lactic acid, lipase, infectious mono screen, and creatine kinase level, were all normal. A chest radiograph and abdominal ultrasound were both unremarkable, and he was admitted.

Further history revealed recent gait instability as well as a change in skin color for a few weeks preceding presentation. Physical examination was significant for generalized pallor and a dusky gray appearance, generalized abdominal tenderness, and right-sided CVA tenderness. Because hyponatremia in the context of nausea, vomiting, fatigue, and skin color changes raised suspicion for Addison's disease, a comprehensive metabolic panel and early morning cortisol were ordered.

The next day he had documented pigmentation of the lower lip and both nipples. Further laboratory evaluation revealed positive thyroid peroxidase antibody, elevated ACTH, cortisol levels nonresponsive to cosyntropin, and persistent hyponatremia and hyperkalemia (see the [Appendix](#table1-2333794X19845074){ref-type="table"} for pertinent laboratory values.). Laboratory data were consistent with primary adrenal insufficiency and Hashimoto's thyroiditis. Hydrocortisone and fludrocortisone were initiated for glucocorticoid and mineralocorticoid replacement, respectively. Because adrenal dysfunction and acute illness can elevate the TSH, the putative Hashimoto's disease was not treated. Thyroid hormone replacement was also held to prevent adrenal crisis from stimulation of the patient's metabolism with thyroid hormone. A respiratory virus panel was positive for coronavirus, which might have precipitated the acute illness. Direct renin level was elevated, and the aldosterone level was low. By day 3, his electrolyte abnormalities and clinical status improved significantly, so he was discharged.

At outpatient follow-up, very long chain fatty acids were normal, eliminating adrenoleukodystrophy as a possible etiology for the adrenal insufficiency. The diabetes autoimmune test group was normal, but the TSH remained elevated with a normal T4, confirming autoimmune hypothyroidism. Follicle-stimulating hormone and luteinizing hormone were normal, eliminating concomitant hypogonadism, but tissue transglutaminase immunoglobulin A was elevated, raising suspicion for celiac disease. Levothyroxine was started and he was referred for intestinal biopsy to confirm celiac disease.

Discussion {#section4-2333794X19845074}
==========

The diagnosis of adrenal insufficiency requires a high index of suspicion. In our case, a 15-year-old male presented with nonspecific gastrointestinal complaints, fatigue, and skin color changes with hyponatremia and hyperkalemia. Our investigation confirmed adrenal insufficiency and ultimately led to a diagnosis of APS type 2. Adrenal insufficiency and APS type 2 are rare diagnoses in the pediatric and adolescent population, although both disorders have been described in children.^[@bibr4-2333794X19845074],[@bibr8-2333794X19845074][@bibr9-2333794X19845074][@bibr10-2333794X19845074]-[@bibr11-2333794X19845074]^

Other investigators have emphasized the wide ranging clinical and laboratory findings associated with adrenal insufficiency, the importance of screening for adrenoleukodystrophy, the importance of alterations in glucose levels, and insulin requirements in type 1 diabetes as it relates to surveillance, and determining etiology and screening for concomitant disorders.^[@bibr4-2333794X19845074],[@bibr8-2333794X19845074][@bibr9-2333794X19845074][@bibr10-2333794X19845074]-[@bibr11-2333794X19845074]^

Although APS type 2 has been reported,^[@bibr12-2333794X19845074][@bibr13-2333794X19845074][@bibr14-2333794X19845074]-[@bibr15-2333794X19845074]^ there are few reports of pediatric patients.^[@bibr14-2333794X19845074],[@bibr15-2333794X19845074]^ There is a need for continued surveillance over a lifetime, as there is potential for development of other autoimmune disorders even decades after the initial diagnosis.

In a study of 18 pediatric patients with primary adrenal insufficiency, hypotension was the presenting sign in 13, hyperpigmentation in 12, hyponatremia in 16, and hyperkalemia in 9. Of 15 who underwent a cosyntropin stimulation test, all failed.^[@bibr16-2333794X19845074]^ Our patient did not have hypotension, yet he had hyperpigmentation, hyponatremia, hyperkalemia, and failed a cosyntropin stimulation test.

The Endocrine Society recently published a clinical practice guideline that details recommendations for both diagnosis and treatment of primary adrenal insufficiency.^[@bibr2-2333794X19845074]^ The cosyntropin stimulation test is recommended for establishing the diagnosis of adrenal insufficiency, together with measurement of plasma ACTH, renin, and aldosterone levels.^[@bibr2-2333794X19845074]^ Treatment includes replacement of both glucocorticoid and mineralocorticoid hormones with hydrocortisone and fludrocortisone, respectively.^[@bibr2-2333794X19845074]^

Numerous are the etiologies of primary adrenal insufficiency, including autoimmune (isolated or part of APS), adrenal injury, infectious, congenital adrenal hyperplasia, drug-induced, or metabolic disorders such as mitochondrial diseases or adrenoleukodystrophy.^[@bibr2-2333794X19845074]^ Thus, effective treatment must be directed toward the underlying cause.

When initiating hormone therapy for treatment of an APS with both adrenal insufficiency and thyroid disease, it is important to be aware that thyroid hormone therapy can initially cause an adrenal crisis with stimulation of increased metabolism of corticosteroids by the hepatic system. Thus, thyroid hormone replacement is usually postponed until appropriate adrenal hormone replacement has occurred.^[@bibr3-2333794X19845074]^

Conclusion {#section5-2333794X19845074}
==========

Adrenal insufficiency is a rare diagnosis in pediatric patients and timely diagnosis is crucial to prevent life-threatening complications. Clinicians must maintain a high index of suspicion when there are any signs, symptoms, or laboratory findings suggesting adrenal pathology. Once the diagnosis is made, it is imperative to determine etiology. The presence of adrenal antibodies confirms an autoimmune cause. Autoimmune adrenal disease may be isolated or associated with a cluster of other autoimmune diseases referred to as APS. It is important to screen for other autoimmune diseases in patients with confirmed autoimmune adrenal insufficiency to adequately treat these patients and avoid complications and sequela.
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Laboratory Values.

![](10.1177_2333794X19845074-table1)

                                             Day 1   Day 2 [am]{.smallcaps}   Day 2 [pm]{.smallcaps}   Day 3   Follow-up   Reference Range
  ------------------------------------------ ------- ------------------------ ------------------------ ------- ----------- ------------------
  Sodium                                     127     130                      125                      135     142         135-145 mmol/L
  Potassium                                  4.9     5.6                      5.4                      5.8     4.8         3.5-5.2 mmol/L
  Glucose                                    92      96                       100                      144     89          60-99 mg/dL
  TSH                                        8.54    ---                      ---                      ---     6.13        0.40-4.50 µIU/mL
  FT4                                        1.3     ---                      ---                      ---     1.1         0.8-1.80 ng/dL
  Cortisol                                   ---     1.9                      ---                      ---     ---         4.0-27.0 µg/dL
  Adrenal antibodies                         ---     ---                      1:4 titer                ---     ---         \<1:2 titer
  ACTH                                       ---     ---                      \>1250                   ---     ---         5-46 pg/mL
  Aldosterone                                ---     ---                      \<3.0                    ---     ---         \<23.3 ng/dL
  Direct renin                               ---     ---                      1944                     ---     12.4        3.1-57.1 pg/mL
  Cosyntropin test: cortisol at 30 minutes   ---     ---                      2.1                      ---     ---         4.0-27.0 µg/dL
  Cosyntropin test: cortisol at 60 minutes   ---     ---                      2                        ---     ---         4.0-27.0 µg/dL
  Thyroglobulin antibody                     ---     ---                      \<20                     ---     ---         0.0-20.0 IU/mL
  Thyroid peroxidase antibody                ---     ---                      64                       ---     ---         0.0-35 IU/mL
  FSH                                        ---     ---                      ---                      ---     3.2         1.6-11.0 mIU/mL
  LH                                         ---     ---                      ---                      ---     3.8         1.3-7.2 mIU/mL

Abbreviations: TSH, thyroid-stimulating hormone; FT4, free thyroxine; ACTH, adrenocorticotropic hormone; FSH, follicle-stimulating hormone; LH, luteinizing hormone.
